TIC10 isomer
(Synonyms: ONC201 isomer) 目录号 : GC10350
TIC10异构体是TIC10的异构体。
Cas No.:41276-02-2
Sample solution is provided at 25 µL, 10mM.
TIC10 (TRAIL-inducing compound 10) is a potent and stable small molecule that is orally active. It induces TRAIL transcriptionally independent of p53 and crosses the blood-brain barrier. [1]
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an apoptosis inducer in a variety of human cancer cell lines. It also acts as a tumor suppressor during immune surveillance but the function is lost in cancer progression. [1]
TIC10 caused a prominent and long-lasting production of TRAIL on cell surface of tumor cell.
TIC10 also led to TRAIL-mediated apoptosis in HCT116 p53-/- cells. In addition, TIC10 inactivated Akt and ERK cooperatively lead to the nuclear translocation of Foxo3a and ensuing TRAIL up-regulation. [1]
In mouse caner xenograft, TIC10 showed TRAIL-dependent antitumor effect. It caused tumor-specific cell death by RAIL-mediated direct and bystander effects. TIC10 is also an effective antitumor agent for orthotopic human glioblastoma multiforme tumors. [1]
Reference:
1. Allen JE, Krigsfeld G, Mayes PA et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17.
| Cell experiment [1]: | |
|
Cell lines |
HCT116 Bax-/- and HCT116 p53-/- cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
1.25, 2.5, 5 and 10 μM; 24, 48 or 72 hours |
|
Applications |
In TRAIL-sensitive HCT116 p53-/- cells, TIC10 induced an increase in sub-G1 DNA content suggestive of cell death in a p53-independent and Bax-dependent manner. In TRAIL-resistant Bax-null HCT116 human colon cancer cells, TIC10 (10 μM, 72 h) dose-dependently increased TRAIL mRNA and induced TRAIL protein localization on the cell surface in a p53-independent manner. |
| Animal experiment [2]: | |
|
Animal models |
Female athymic nu/nu mice subcutaneous xenografted with HCT116 p53-/- tumor and MDA-MB-231 human triple-negative breast cancer. |
|
Dosage form |
50, 80 or 100 mg/kg; intraperitoneal injection; administered on days 0, 3, and 6 |
|
Application |
In mice bearing the HCT116 p53-/- xenograft, TIC10 caused tumor regression. TIC10 also induced regression of MDA-MB-231 human triple-negative breast cancer xenografts. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Allen JE, Krigsfeld G, Mayes PA et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. |
|
| Cas No. | 41276-02-2 | SDF | |
| 别名 | ONC201 isomer | ||
| 化学名 | 7-benzyl-10-(2-methylbenzyl)-2,3,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(10H)-one | ||
| Canonical SMILES | O=C1C(CN(CC2=CC=CC=C2)CC3)=C3N(CC4=CC=CC=C4C)C5=NCCN15 | ||
| 分子式 | C24H26N4O | 分子量 | 386.49 |
| 溶解度 | ≥ 6.43mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5874 mL | 12.9369 mL | 25.8739 mL |
| 5 mM | 0.5175 mL | 2.5874 mL | 5.1748 mL |
| 10 mM | 0.2587 mL | 1.2937 mL | 2.5874 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet